Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia

The pathological increase of clonal IgM in Waldenström macroglobulinemia can be associated with acquired von Willebrand syndrome and can be a major risk of bleeding symptoms in this subgroup of patients with Waldenström macroglobulinemia. The Bruton tyrosine kinase inhibitor ibrutinib is one of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Poza, María, Íñiguez, Rodrigo, Zamanillo, Irene, Redondo, Sara, Alonso, Rafael, Martínez-López, Joaquín, Jiménez-Ubieto, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404625/
https://www.ncbi.nlm.nih.gov/pubmed/34471509
http://dx.doi.org/10.1177/20406207211039326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404625/
https://www.ncbi.nlm.nih.gov/pubmed/34471509
http://dx.doi.org/10.1177/20406207211039326

Ejemplares similares